|
|
Article: Minimally Invasive Device Approved to Treat Liver Cancer, Fibroids, Tumors, and Bleeding.
- Article from:
- PR Newswire
- Article date:
- October 13, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEWNAN, Ga., Oct. 13 /PRNewswire/ -- CeloNova BioSciences, Inc. has received approval from its European regulatory body, the British Standards Institution, to expand the list of medical indications for which Embozene(TM) Microspheres may be used and to add a tenth size of the product.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081001/CLW080LOGO-b )
(Photo: http://www.newscom.com/cgi-bin/prnh/20081007/CLTU035-b )
(Photo: http://www.newscom.com/cgi-bin/prnh/20090916/CL76973)
In Europe, Embozene(TM) Microspheres are now approved for the treatment of liver cancer, uterine fibroids, tumors of the head, neck, torso, and skeletal system; for ...
Related newspaper, magazine, and journal articles:
|
|
Article: CeloNova BioSciences Announces World's First Line ...
PR Newswire Europe;
September 9, 2007 ;
700+ words
... ... 9 /PRNewswire/ -- CeloNova BioSciences, Inc. ("CeloNova ... particles, Embozene(TM) Color-Advanced Microspheres ... in mind. Embozene(TM) Color-Advanced Microspheres ... procedure." Embozene(TM) Color-Advanced Microspheres ... physician preference. About CeloNova BioSciences, Inc. ...
|
|